Don't judge a JAK2 inhibitor by spleen response alone

Splenic extramedullary hematopoiesis in myelofibrosis is shaped by transcriptomic and epigenetic dysregulation.

Cell stem cell·2026

Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis.

Blood advances·2026

Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms.

Leukemia·2026

Sapablursen for Erythrocytosis Control in Patients with Polycythemia Vera.

Blood·2026

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment-related pathways.

British journal of haematology·2026

Menin-dependent megakaryocyte proliferation and fibrosis in myeloproliferative neoplasms.

Cancer cell·2026

Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers.

The Lancet. Haematology·2026

Beyond maximum grade: key regulatory considerations in adverse event reporting.

The Lancet. Haematology·2026

Beyond maximum grade: long-term toxicity and survivorship in haematological malignancies.

The Lancet. Haematology·2026

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

The Lancet. Haematology·2026

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.

The Lancet. Haematology·2026

Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.

The Lancet. Haematology·2026

Toxicological and pharmacodynamic evaluation of Nixodine-S [(S)-6-Methylnicotine] relative to (S)-nicotine.

Toxicology reports·2026

Correction: Barros et al. Effects of Eriobotrya japonica (Thunb.) Lindl. Leaf Extract on Zebrafish Embryogenesis, Behavior, and Biochemical Pathways. Molecules 2025, 30, 3252.

Molecules (Basel, Switzerland)·2026

Correction: Almeida et al. Diterpenes: Nature's Hidden Gems of Immunomodulation. Int. J. Mol. Sci. 2025, 26, 2250.

International journal of molecular sciences·2026

Corrigendum to: The Integration of Systematic Pharmacology and Experimental Validation to Explain the Mechanism of Action of Wuling Capsule in the Treatment of NAFLD.

Combinatorial chemistry & high throughput screening·2026

Poorly labeled CBD and related cannabinoid oils marketed in Europe: a hidden risk for consumers? Insights from a long-term study.

Analytical and bioanalytical chemistry·2026

Black Elderberry Exposure in Apparent Idiopathic Mild Acute Pancreatitis: A Case Report.

Cureus·2026

Related Experiment Videos

Don't judge a JAK2 inhibitor by spleen response alone

Related Concept Videos

Splenic extramedullary hematopoiesis in myelofibrosis is shaped by transcriptomic and epigenetic dysregulation.

Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis.

Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms.

Sapablursen for Erythrocytosis Control in Patients with Polycythemia Vera.

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment-related pathways.

Menin-dependent megakaryocyte proliferation and fibrosis in myeloproliferative neoplasms.

Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers.

Beyond maximum grade: key regulatory considerations in adverse event reporting.

Beyond maximum grade: long-term toxicity and survivorship in haematological malignancies.

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.

Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.

Toxicological and pharmacodynamic evaluation of Nixodine-S [(S)-6-Methylnicotine] relative to (S)-nicotine.

Correction: Barros et al. Effects of Eriobotrya japonica (Thunb.) Lindl. Leaf Extract on Zebrafish Embryogenesis, Behavior, and Biochemical Pathways. Molecules 2025, 30, 3252.

Correction: Almeida et al. Diterpenes: Nature's Hidden Gems of Immunomodulation. Int. J. Mol. Sci. 2025, 26, 2250.

Corrigendum to: The Integration of Systematic Pharmacology and Experimental Validation to Explain the Mechanism of Action of Wuling Capsule in the Treatment of NAFLD.

Poorly labeled CBD and related cannabinoid oils marketed in Europe: a hidden risk for consumers? Insights from a long-term study.

Black Elderberry Exposure in Apparent Idiopathic Mild Acute Pancreatitis: A Case Report.

Related Experiment Videos

Don't judge a JAK2 inhibitor by spleen response alone

Related Concept Videos

Related Articles